ChristopherRyanHeeryMD

PubMed

• 91 citations
  A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
  Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole
  Clinical Cancer Research. 2011-11-08
• 41 citations
  A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
  Margaret E. Gatti-Mays, Julius Strauss, Renee N. Donahue, Claudia Palena, Jaydira Del Rivero
  Clinical Cancer Research. 2019-08-15
• 280 citations
  Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
  Julius Strauss, Christopher R. Heery, Jeffrey Schlom, Ravi A. Madan, Liang Cao
  Clinical Cancer Research. 2018-03-15

Journal Articles

• Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma  
  Bilusic, M, Heery, CR, Arlen, PM, Rauckhorst, M, Apelian, D, Tucker, JA, Jochems, C, Schlom, J, Gulley, JL, Madan, RA, Cancer Immunol Immunother, 1/1/2014
• A phase I study of intraprostatic administration of PSA-TRICOM vaccine in men with locally recurrent or progressive prostate cancer  
  Gulley, JL, Heery, CR, Madan, RA, Walter, BA, Merino, MJ, Vergati, M, Poole, DJ, Cereda, V, Tsang, K, Dahut, WL, Schlom, J, Pinto, PA, Cancer Immunol Immunother, 1/1/2013
• Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer  
  Gulley, JL, Madan, RA, Heery, CR, Am Soc Clin Oncol Educ Book, 1/1/2013
• Clinical evaluation of TRICOM vector therapeutic cancer vaccines  
  Madan, RA, Bilusic, M, Heery, C, Schlom, J, Gulley, JL, Seminars in Oncology, 6/1/2012
• Unusual CNS presentation of thyroid cancer  
  Heery CR, Engelhard HH, Slavin KV, Michals EA, Villano JL, Clinical Neurology and Neurosurgery, 1/1/2012
• Combination of vaccine and immune checkpoint inhibitor safe with encouraging clinical activity  
  Madan, RA, Heery, CR, Gulley, JL, OncoImmunology, 1/1/2012
• Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response  
  Kim, JW, Bilusic, M, Heery, CR, Madan, RA, Cancers, 1/1/2012
• Combining radiation and therapeutic cancer vaccines: a synergistic approach  
  Heery, CR, Hodge, JW, Gulley, JL, Breast Cancer Manage, 1/1/2012
• Modern Immunotherapy for the treatment of prostate cancer  
  Heery, CR, Madan, RA, Drug Discov Today: Therapeutic Strategies, 1/1/2011
• Join now to see all

Books/Book Chapters

• Am Soc Clin Oncol Educ Book 
  Chapter: Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer. 
  Page 166 - 170GulleyJL, Madan RA, Heery CR2013
• DNA Topoisomerases and Cancer 
  Chapter: Topoisomerase II Inhibitors: Current Use and Prospects. 
  Olivier Mir, William Dahut, Francois Goldwasser, and Christopher Heery2012
• Emerging Cancer Therapeutics: Prostate Cancer 
  Chapter: Emerging treatment strategies for metastatic prostate cancer: The next step forward. 
  Heery CR, Bilusic M, Madan R2011
• ASCO Education Book 
  Chapter: Immune Targeting of Prostate Cancer. 
  Schlom J, Madan RA, Bilusic M, Heery CR, Hodge JW, Gulley JL2011
• Join now to see all

Abstracts/Posters

• Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
  Christopher Heery, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Calculation of an immunoscore based on extensive flow cytometry analysis of PBMCs from metastatic breast cancer patients treated with docetaxel alone or in combination...
  Grenga I, Donahue RN, Kim PS, Dempsy B, Gulley JL, Heery CR, Madan RA, Schlom J, Farsaci B, J Clin Oncol, ASCO Breast Cancer Symposium, 1/1/2013
• Safety profile of poxviral vaccines: NCI experience.
  Kim JW, Marte JL, Bilusic M, Singh NK, Heery CR, Madan RA, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Gulley JL, J Clin Oncol, Genitourinary Cancers Symposium, 1/1/2013
• Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa.
  Gulley JL, Madan RA, Stein WD, Wilkerson J, Dahut WL, Heery CR, Schlom J, Wilding G, DiPaola RS, J Clin Oncol, ASCO Genitournary Cancers Symposium, 1/1/2013
• A phase 2 randomized clinical trial of Samarium-153 EDTMP (Sm-153) +/- PSA-TRICOM vaccine in metastatic castration resistant prostate cancer (mCRPC) after docetaxel.
  C. Heery, R. Madan, M. Bilusic, J. Kim, N. Singh, M. Rauckhorst, S. Steinberg, W. Dahut, C. Chen, R. DiPaola, M. Stein, W. Stadler, D. Panicali, J. Hodge, J. Schlom, J..., GU ASCO Meeting, 1/1/2013
• A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA TRICOM, in metastatic, castration resistant prostate cancer.
  Singh NK, Kim JW, Heery CR, Dahut WL, Couvillon A, Rauckhorst M, McMahon S, Schlom J, Fojo A, Arlen PM, Gulley JL, Madan RA, J Clin Oncol, ASCO Annual Meeting, 1/1/2013
• Impact of Androgen Deprivation Therapy on the Thymus and the Production of Naive T-cells.
  Madan RA, Hakim F, Jochems C, Heery CR, O'Sullivan GC, Singh H, Surolia I, Tsang KY, Gress R, Schlom J, Gulley J, SITC Annual Meeting, 1/1/2013
• A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer.
  Madan RA, Singh NK, Gramza AW, Fojo A, Heery CR, Kim JW, McMahon S, Rauckhorst M, King TH, Apelian D, Schlom J, Gulley JL, J Clin Oncol, ASCO Annual Meeting, 1/1/2013
• Safety profile of recombinant poxviral TRICOM vaccines.
  Kim JW, Marte JL, Singh NK, Heery CR, Madan RA, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Kantoff PW, Gulley JL, J Clin Oncol, ASCO Annual Meeting, 1/1/2013
• A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-, MUC1-TRICOM.
  C. Heery, N. Ibrahim, R. Madan, M. Mohebtash, P. Arlen, M. Bilusic, J. Kim, N. Singh, S. McMahon, S. Hodge, S. Steinberg, J. Schlom, J. Hodge, J. Gulley, San Antonio Breast Cancer Symposium, 1/1/2012
• A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA expressing cancers.
  M. Bilusic, J.L. Gulley, J.W. Hodge, K.Y. Tsang, P. M. Arlen, C.R. Heery, M. Rauckhorst, S. McMahon, C. Intrivici, D. Poole, C. Jochems, J. Schlom, R.A. Madan, J Clin Oncol, 1/1/2012
• A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFI...
  Marshall J, Hwang JJ, Pishvaian MJ, He AR, Weiner LM, Sandene EK, Gulley JL, Heery CR, Schlom J, Speyer S, Richman J, Ferraro J, Coeshott C, Cohn A, Appelian D, Rodell TC, J Clin Oncol, ASCO Annual Meeting, 1/1/2012
• First-in-human phase I trial of NHS-IL12 in advanced solid tumors.
  Kim JW, Heery CR, Bilusic M, Singh NK, Madan RA, Sabzevari H, Schlom J, Gulley JL, J Clin Oncol, ASCO Annual Meeting, 1/1/2012
• Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer ...
  C.R. Heery, R.A. Madan, M. Bilusic, J.W. Kim, N.K. Singh, M. Rauckhorst, C. Chen, W.L. Dahut, W.M. Stadler, R.S. DiPaola, M.N. Stein, J.W. Hodge, J. Schlom, J.L.Gulley, J Clin Oncol, ASCO Annual Meeting, 1/1/2012
• A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-, MUC1-TRICOM.
  C. Heery, N. Ibrahim, R. Madan, M. Mohebtash, P. Arlen, M. Bilusic, J. Kim, N. Singh, S. McMahon, S. Hodge, S. Steinberg, J. Schlom, J. Hodge, J. Gulley, ESMO Annual Meeting, 1/1/2012
• Combining Vaccines with other therapeutics: A strategy to accelerate proof of concept studies?
  Gulley J.L., Heery C.R., Bilusic M., Kim J., Stadler W., DiPaola R., Ibrahim N., Madan R., Society for Immunotherapy of Cancer Annual Meeting, 11/1/2011
• Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer.
  C.R. Heery, P. A. Pinto, J. Schlom, K.Y. Tsang, R.A. Madan, D. Poole, M. Vergati, B. Walter Rodriguez, M. Merino, J.L. Gulley, J Clin Oncol, ASCO Annual Meeting, 1/1/2011
• A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA.
  R.A. Madan, M. Bilusic, J. W. Hodge, K.Y. Tsang, P. M. Arlen, C.R. Heery, M. Rauckhorst, S. McMahon, C. Intrivici, T. A. Ferrara, A. Cohn, D. Apelian, A. Franzusoff, Z..., J Clin Oncol, 1/1/2011
• Intraprostatic vaccine administration in patients with locally recurrent prostate cancer.
  Heery CR, Pinto PA, Schlom J, Tsang KY, Madan RA, Poole D, Vergati M, Walter Rodriguez B, Merino M, Gulley JL, J Clin Oncol, 1/1/2011
• Immune Targeting of Prostate Cancer.
  Schlom J, Madan RA, Bilusic M, Heery CR, Hodge JW, Gulley JL, GU ASCO Presentation, 1/1/2011
• A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC).
  M. Bilusic, J. L. Gulley, C. Heery, A. B. Apolo, P. M. Arlen, M. Rauckhorst, S. McMahon, W. L. Dahut, J. Schlom, R. A. Madan, J Clin Oncol, 1/1/2011
• Prostvac: A promising new therapeutic vaccine for Prostate Cancer.
  Gulley JL, Madan RA, Heery CR, Bilusic M, Dahut W, Schlom, J, Society of Urologic Oncology, 12/1/2010
• Flutamide with or without a Poxviral-based Therapeutic Cancer Vaccine in patients with nonmetastatic Castration-Resistant Prostate Cancer (CRPC).
  Madan RA, Bilusic M, Heery CR, Apolo AB, Arlen PM, Dahut WL, Schlom J, Gulley JL, Society of Urologic Oncology, 12/1/2010
• Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade g...
  Heery CR, Desjardins A, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Friedman AH, Reardon DA, and Friedman HS, Journal of Clinical Onocology, ASCO Annual Meeting Proceedings, 1/1/2006
• Join now to see all